BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24660985)

  • 21. The interplay of sun damage and genetic risk in Australian multiple and single primary melanoma cases and controls.
    McMeniman EK; Duffy DL; Jagirdar K; Lee KJ; Peach E; McInerney-Leo AM; De'Ambrosis B; Rayner JE; Smithers BM; Soyer HP; Sturm RA
    Br J Dermatol; 2020 Aug; 183(2):357-366. PubMed ID: 31794051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations.
    Goldstein AM; Landi MT; Tsang S; Fraser MC; Munroe DJ; Tucker MA
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2208-12. PubMed ID: 16172233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
    Holland EA; Schmid H; Kefford RF; Mann GJ
    Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries.
    Goldstein AM; Chaudru V; Ghiorzo P; Badenas C; Malvehy J; Pastorino L; Laud K; Hulley B; Avril MF; Puig-Butille JA; Miniere A; Marti R; Chompret A; Cuellar F; Kolm I; Mila M; Tucker MA; Demenais F; Bianchi-Scarra G; Puig S; de-Paillerets BB
    Int J Cancer; 2007 Aug; 121(4):825-31. PubMed ID: 17397031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recommendations for genetic testing and management of individuals genetically at-risk of cutaneous melanoma].
    Avril MF; Bahadoran P; Cabaret O; Caron O; de la Fouchardière A; Demenais F; Desjardins L; Frébourg T; Hammel P; Leccia MT; Lesueur F; Mahé E; Martin L; Maubec E; Remenieras A; Richard S; Robert C; Soufir N; Stoppa-Lyonnet D; Thomas L; Vabres P; Bressac-de Paillerets B
    Ann Dermatol Venereol; 2015 Jan; 142(1):26-36. PubMed ID: 25600792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
    Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
    Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic variations of patients with familial or multiple melanoma in Southern Brazil.
    Grazziotin TC; Rey MC; Bica CG; Pinto LA; Bonamigo RR; Puig-Butille JA; Cuellar F; Puig S
    J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):e179-85. PubMed ID: 22621339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
    Sargen MR; Calista D; Elder DE; Massi D; Chu EY; Potrony M; Pfeiffer RM; Carrera C; Aguilera P; Alos L; Puig S; Elenitsas R; Yang XR; Tucker MA; Landi MT; Goldstein AM
    J Am Acad Dermatol; 2020 Sep; 83(3):860-869. PubMed ID: 32283231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted germline sequencing of patients with three or more primary melanomas reveals high rate of pathogenic variants.
    Li C; Liu T; Tavtigian SV; Boucher K; Kohlmann W; Cannon-Albright L; Grossman D
    Melanoma Res; 2020 Jun; 30(3):247-251. PubMed ID: 31567591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
    Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
    Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDKN2A and MC1R variants found in Cypriot patients diagnosed with cutaneous melanoma.
    Koulermou G; Shammas C; Vassiliou A; Kyriakides TC; Costi C; Neocleous V; Phylactou LA; Pantelidou M
    J Genet; 2017 Mar; 96(1):155-160. PubMed ID: 28360400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malignant and benign tumors associated with multiple primary melanomas: just the starting block for the involvement of MITF, PTEN and CDKN2A in multiple cancerogenesis?
    Pollio A; Tomasi A; Seidenari S; Pellacani G; Rodolfo M; Frigerio S; Maurichi A; Turchetti D; Bassoli S; Ruini C; Ponti G
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):755-7. PubMed ID: 23802662
    [No Abstract]   [Full Text] [Related]  

  • 35. Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer.
    Puig-Butille JA; Escámez MJ; Garcia-Garcia F; Tell-Marti G; Fabra À; Martínez-Santamaría L; Badenas C; Aguilera P; Pevida M; Dopazo J; del Río M; Puig S
    Oncotarget; 2014 Mar; 5(6):1439-51. PubMed ID: 24742402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation.
    Veinalde R; Ozola A; Azarjana K; Molven A; Akslen LA; Doniņa S; Proboka G; Cēma I; Baginskis A; Pjanova D
    Melanoma Res; 2013 Jun; 23(3):221-6. PubMed ID: 23546221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Y152X MC1R gene mutation: occurrence in ethnically diverse Jewish malignant melanoma patients.
    Galore G; Azizi E; Scope A; Pavlotsky F; Yakobson E; Friedman E
    Melanoma Res; 2007 Apr; 17(2):105-8. PubMed ID: 17496785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First detection of the melanoma-predisposing proline-48-threonine mutation of p16 in Hungarians: was there a common founder either in Italy or in Hungary?
    Széll M; Balogh K; Dobozy A; Kemény L; Oláh J
    Melanoma Res; 2007 Aug; 17(4):251-4. PubMed ID: 17625456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters.
    Karagianni F; Njauw CN; Kypreou KP; Stergiopoulou A; Plaka M; Polydorou D; Chasapi V; Pappas L; Stratigos IA; Champsas G; Panagiotou P; Gogas H; Evangelou E; Tsao H; Stratigos AJ; Stefanaki I
    Acta Derm Venereol; 2018 Oct; 98(9):862-866. PubMed ID: 29774366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
    Nielsen K; Harbst K; Måsbäck A; Jönsson G; Borg A; Olsson H; Ingvar C
    Melanoma Res; 2010 Aug; 20(4):266-72. PubMed ID: 20526219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.